AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02668510
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection of normal saline immediately following shockwave therapy
Trial: NCT02839096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
Trial: NCT01436149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Trial: NCT00573508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT03860870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects ingest placebo tablets
Trial: NCT02183948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00307801
Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Trial: NCT00307801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Trial: NCT03812731
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
Trial: NCT02575963
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
Trial: NCT03278275
Drug: One injection of 68Ga-NOTA-AE105
RxNorm normalized name: Gel-One Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of 68Ga-NORA-AE105
Trial: NCT03094416
Drug: levothyroxine sodium capsule
RxNorm normalized name: levothyroxine sodium Oral Capsule
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
Trial: NCT03094416
Drug: Proton pump inhibitor (PPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
Trial: NCT03094416
Drug: Levothyroxine Sodium (LT4) Tablets
RxNorm normalized name: Levothyroxine Sodium Tablets
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
Trial: NCT02434640
Drug: BAY1128688
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)
Trial: NCT02434640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)
Trial: NCT02434640
Drug: BAY1128688
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Multiple dose for 28 days (premenopausal women)
Trial: NCT01016912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, daily, 48 weeks
Trial: NCT00212082
Drug: doxorubicin, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00284947
Drug: MMF/EC-MPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g MMF or 720mg EC-MPS p.o twice daily
Trial: NCT00284947
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
Trial: NCT00121251
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04008290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
Trial: NCT04052711
Drug: FMX-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648440
Drug: ProAmatine® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, single dose fed
Trial: NCT00570986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
Trial: NCT00828594
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01263080
Drug: folic acid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: folic acid placebo 1 tablet QD
Trial: NCT01263080
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: folic acid 0.4mg QD
Trial: NCT02183662
Drug: Placebo to BI 224436
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04404491
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
Trial: NCT04404491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 200mg,d1,15,29,43,57,I.V
Trial: NCT02118467
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
Trial: NCT02118467
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
Trial: NCT02643212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432172
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00863278
Drug: Kligman's Trio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
Trial: NCT03968393
Drug: Non-vitamin K oral anticoagulant (NOAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
Trial: NCT03815929
Drug: Estradiol 100 Micrograms Patch
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard
Trial: NCT03815929
Drug: Estradiol Patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized
Trial: NCT03674411
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV over 2 hours
Trial: NCT03674411
Drug: Total Body Irradiation (TBI)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 cGy twice daily
Trial: NCT00700479
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02431559
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD was administered as an IV infusion in accordance with local prescribing information.
Trial: NCT00305188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00305188
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV administration
Trial: NCT02612272
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intra-articular ketorolac
Trial: NCT01623570
Drug: Pergoveris: 150IU r-hFSH + 75IU r-hLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed formulation of two recombinant gonadotropins
Trial: NCT01623570
Drug: Menopur: HMG-HP (150 IU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
Trial: NCT00434746
Drug: ILV-094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
Trial: NCT00687193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00687193
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00687193
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00687193
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00687193
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00687193
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg BID, 3 blinded tablets administered BID for 12 weeks
Trial: NCT00302731
Drug: Estradiol , estriol , progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00302731
Drug: estradiol, progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00933816
Drug: sorafenib, cisplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
Trial: NCT01692457
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
Trial: NCT00397501
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
Trial: NCT03768492
Drug: Caffeine anhydrous 5% added to Lipoderm Cream Base.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
Trial: NCT04334824
Drug: Angiotensin-converting enzyme (ACE) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
Trial: NCT02986321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control
Trial: NCT01632007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04301271
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks 40 mg Simvastatin add-on
Trial: NCT04301271
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks Placebo add-on
Trial: NCT00967811
Drug: Formulation E1 of L-PPDS
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Trial: NCT00967811
Drug: Formulation E2 of L-PPDS
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
Trial: NCT03818256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for once-daily oral dosing
Trial: NCT00280540
Drug: Valsartan/Hydrochlorothiazide
RxNorm normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02616120
Drug: SQJZ herbal mixtures
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
Trial: NCT02616120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
Trial: NCT01884675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, film-coated, ambrisentan-matching placebo tablet for single oral dose
Trial: NCT01285557
Drug: Fluorouracil/cisplatin (control arm)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
Trial: NCT00033683
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00033683
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00033683
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00033683
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02061020
Drug: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.
Trial: NCT03914131
Drug: Xinnaoning Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
Trial: NCT01491802
Drug: LAMA/LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
Trial: NCT01005966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo and washout treatment
Trial: NCT01005966
Drug: 675 ppmf toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose response
Trial: NCT00231959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT03741075
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Trial: NCT00001256
Drug: prednisone and methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04087733
Drug: OZODROP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
Trial: NCT00039377
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and IV
Trial: NCT02420717
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00039377
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT00039377
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02420717
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02420717
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02420717
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02420717
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT02419495
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02419495
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02419495
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02419495
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02419495
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02471898
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02471898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02079077
Drug: Acetylsalicylic Acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
Trial: NCT03758612
Drug: Placebo suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for TBI-223 oral Suspension; orally administered.
Trial: NCT02373176
Drug: [14C]PRC 4016 (Icosabutate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03003325
Drug: AOP2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
Trial: NCT01648751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Trial: NCT02991768
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is matched to the study drug.